MedDRA - Myocardial infarction MedDRA - Diabetes
Conditions
Interventions
Group 1: Control group (diabetic patients with STEMI n = 30 ) was given the standard medical
treatment (Aspirin 300 mg once daily , low molecular weight heparin 0.5
mg/kg/day IV , and clopidogrel 600
Sponsors
Faculty of medicine - Tanta university
Eligibility
Sex/Gender
All
Age
45 Years to 59 Years
Inclusion criteria
Inclusion criteria: diabetic patients with STE MI
Exclusion criteria
Exclusion criteria: Patients were excluded from the study if they had any one of the following criteria: previous myocardial infarction, previous PCI or coronary artery bypass intervention, were currently on DPP- 4 inhibitors, steroidal and non- steroidal anti-inflammatory drugs, has long term immunosuppressive therapy, cancer and infectious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| What? the addition of vild to standard medical treatment of MIRI (myocardial ischaemia-reperfusion injury) could increase the effectiveness of it through recruitment of CD4+CD25+ Treg cells. How? Through the assessment of percentage of changes in nitric oxide, ischemia modified albumin, highly sensitive C reactive protein and interferon gamma levels, myeloperoxidase activity, CD4 +CD25+ Treg cells count and Transforming growth factor-beta1 level in the studied groups. When? It is measured twice for each patient; reading 1 is baseline reading at time of admission before starting the treatment and reading 2 measured 72 hours after starting the medical treatment. | — |
Countries
Egypt
Contacts
Public ContactFatma H Rizk
Faculty of medicine - tanta university
Outcome results
None listed